CytoReason cofounder and CEO David Harel credit: Geva Talmor Israeli AI disease models co CytoReason raises $80m

Six of the world’s top 10 pharma companies use CytoReason’s technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas.

Pof. Ehud Raanani   credit: Sheba Medical Center The heart surgeon with a $300m exit: We had glitches

The sale to Edwards Lifesciences vindicates Innovalve's solution for the most common, and most challenging, heart valve disorder, and also Sheba Hospital's innovation model.

Ofer Gonen credit: Eran Lavi MediWound raises $25m, acquisition still possible

Swedish company Mölnlycke Health Care, an international leader in the field of treating wounds, led the private placement.

Prof. Ehud Raanani credit: Sheba Edwards Lifesciences buys Israeli co Innovalve Bio Medical

Sources estimate that Edwards will pay more than $300 million for Innovalve's trans-catheter mitral valve replacement device.

Yuval Soiref (far left) Mike Tyson (center) credit: Moses801 Yuval Soiref to market Mike Tyson medical cannabis in Germany

The Israeli businessman's long term aim is to build Phcann in the medical cannabis market in Europe including the UK, as well as in Australia.

Ofer Gonen credit: Eran Lavi MediWound jumps on reports of $400m bid by Solventum

The Israeli company has developed a pineapple-plant based product for treatment of burns and wounds.

Daria Lemann-Blumenthal credit: Tim Kerr Alcon completes acquisition of Israeli co Belkin Vision

Alcon will make an immediate payment of $81 million and a further $385 million in milestone payments, according to the product's success on the market.

Digital medicine credit: Shutterstock AI care co K Health raises $50m at $900m valuation

K Health CEO Allon Bloch: K Health solves the need to make primary care visits highly personalized by giving doctors AI super powers that enable them to practice at the top of their license.

Teva CEO Richard Francis  credit: Teva spokesperson US competition watchdog probing Teva's inhaler patents - report

According to "The Washington Post", the Federal Trade Commission is investigating whether Teva and other companies are using slight changes to products to extend patents.

Google offices Mountain View, California Photo: Shutterstock achinthamb Alphabet closing Verily health data Israel R&D center

Verily Life Sciences has 25 employees in Tel Aviv and Haifa.

Teva executive VP of global R&D and chief medical officer Dr. Eric A. Hughes  credit: Teva Teva exec reveals the AI tools pharma really wants

Fantasies of an AI revolution in drugs have met the reality of the industry's conservatism. But Teva’s head of R&D offers a glimpse into the AI tools his company actually uses, and is looking for. Startups take note.

Sensi.AI founders credit: Omer Hacohen Israeli care intelligence co Sensi.AI raises $31m

Sensi.AI's advanced audio platform detects and predicts care events while ensuring privacy during home care.

Teva  credit: Cineberg/Shutterstock Teva agrees $750m Israel Tax Authority settlement

The deal resolves all pending litigation on taxes payable by the company for 2008-2020.

Everyone wants a medical school  credit: Tali Bogdanovsky/Shutterstock Will rash of new medical schools solve Israel's doctor shortage?

Four new medical schools are planned in the coming years, but the government is not even aiming to reach the OECD average of doctors per thousand population.

Maurice Ferre illustration Gil Gibli Israeli ultrasound co Insightec raises $150m

The new financing comes several months after Insightec announced layoffs and a going concern qualification was attached to its financial results.

Medical research  credit: Shutterstock Clinical trials in Israel decline sharply

Revenue from trials by international companies in Israeli hospitals fell to NIS 518 million in 2023 from NIS 818 million in 2022.

Teva CEO Richard Francis  credit: Teva spokesperson Teva again king of Tel Aviv castle

After a 130% rise in its share price in the last year, the pharmaceuticals company has left the big two banks and Nice a long way behind.

Yanay Ofran credit: Eyal Izhar Biolojic Design signs Merck deal worth up to €346m

The Israeli biotech company uses AI and computerized biology to develop smart antibodies.

Dr. Yaron Daniely (left) and Dr. Ronny Gal  credit: Cadya Levy The exec who decides which drugs Novartis will develop

Dr. Ronny Gal, Novartis's Chief Strategy and Growth Officer: Our aim is that half our innovative products should come from outside the company.

Avi Spier, Novartis Executive Director Business Development and Licensing  credit: Cadya Levy The scout who learned to look for the quiet ones

Dr. Avi Spier, Executive Director Business Development and Licensing at Novartis, on how to find successful partnerships.

Dr. Tamar Alon   credit: Cadya Levy "We seek star researchers, pioneers in their fields"

Novartis’s Dr. Tamar Alon and Dr. Evan M. Beckman talk about the types of research that can drive the company's growth.

Eliran Elimelech, SNC VP of Ecosystem Development  credit: Cadya Levy Startup Nation Central data reveal the opportunities

Eliran Elimelech, Startup Nation Central VP of Ecosystem Development: Most of the companies are in AI and pharma.

Novartis Israel Country President Elad Maron  credit: Cadya Levy "We want to be a bridge between Israel and the world in biomed"

In Israel, Novartis focuses on marketing and clinical trials, but Country President Elad Maron says, "We know we can do much more. We want to make our mark beyond Israel in the biomedical industry."

Teva  credit: Cineberg/Shutterstock Teva schizophrenia drug Phase III results excite analysts

Evercore ISI analyst Umer Raffat believes that sales could amount to more than $1 billion annually.

Teva CEO Richard Francis credit: Elad Malka Teva hits five-year high after Q1 results

The Israeli pharmaceuticals company has reaffirmed its outlook for 2024 after higher revenue and a narrower loss in the first quarter of 2024.

Biotech credit: Gorodenkoff Shutterstock Israeli biotech co Nectin Therapeutics raises $10m

Nectin develops novel targeted immunotherapies that address resistance to approved immune oncology treatments.

Dollars credit: Colin Watts, Unsplashed Alcon to buy Israeli glaucoma treatment co Belkin Vision

The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.

Dot Compliance founder Doron Sitbon AI that speeds up decision making in biomed

Dot Compliance provides AI-based solutions for quality control in life sciences, where time is a great deal of money.

Hospital  credit: Shutterstock Leumit and Meuhedet awarded new Beersheva hospital

Beersheva's second hospital will be operated by Sheba Medical Center, and is due to open by 2028.

Richard Francis  credit: PR Teva CEO Francis becomes highest paid TASE co exec

Richard Francis's compensation cost $25.7 million in 2023, although that includes incentives for him to join the company.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018